Profiling drug leads by means of in silico and in vitro assays as well as omics is widely used in drug discovery for safety and efficacy predictions. In this study, we evaluate the performances of machine learning models trained on data from gene expression and phenotypic profiling assays, with in vitro assays by means of chemical structure descriptors, for prediction of various drug mechanisms of action and target proteins. Models for several hundred mechanism(s) of actions and protein targets were trained using data on 1484 compounds characterized in both gene expression using L1000 profiles, and phenotypic profiling with cell painting assays. The results indicate that the accuracy of the three profiling technologies varies for different endpoints, and indicate a clear potential synergistic effect if these methods are combined. We also study the effect of predictive accuracy of data from different cell lines for L1000 profiles, showing that the choice of cell line has a non-negligible effect on the predictive accuracy. The results strengthens the idea of integrated approaches for predicting drug targets and mechanisms of action in preclinical drug discovery.
Introduction
Over the past decade, methods have been developed to systematically determine cellular effects of chemical compounds with the aid to improve fields such as drug screening and safety profiling [1, 2, 3] . Important objectives include to predict off-target effects and adverse drug reactions (ADRs), but also to offer insights into compound's Mode-of-Action (MoA) and the establishment of Adverse Outcome Pathways (AOPs).
Pharmaceutical profiling using ligand binding or enzyme assays is the most widely used in vitro methodology, and it is widely implemented in drug discovery safety platforms. Profiling using gene expression is relatively recent, and pioneering work includes Connectivity Map [4] that has been widely used and built upon [5, 6] . L1000 is a high throughput and low cost gene expression profiling method, based on representation of transcriptome by 978 "landmark genes". Recently, datasets with L1000 profiles were made available in Broad LINCS L1000 Connectivity Map project, including profiles for a total of 20K small molecule compounds, of which over 2K compounds were studied systematically in nine human cancer cell lines [6, 7] .
Multiparametric high-content imaging has also proven to be a highly useful and successful technique for understanding biological activity in response to chemical and genetic perturbations. The Broad Bioimage Benchmark Collection (BBBC) is an important publicly available collection of microscopy images. Some of the largest image sets obtained by Cell Painting assay comprise osteosarcoma cells treated by 1.6K known bioactive compounds [8] and by 30K compounds, most of which being derived from diversity-oriented synthesis [9] .
It is hypothesized that chemical compounds with a similar mechanism of action (MoA), which act upon the same signaling pathways, will produce comparable phenotypes, and that analysis of phenotyping profiling data can predict compound mechanism of action [10] . Successful prediction examples include study by Ljosa et al. [11] where 37 compounds are classified to 12 MoA's with 94% prediction accuracy and study by Warchal et al. where 24 compounds are classified to 8 MoA's with over 80% accuracy in several cell lines [8] . On a large scale, predicting of results of particular biological assays on the basis of phenotyping profiling data have been recently undertaken [12, 13] . In particular, in study by Simm et al. information extracted from microscopy-based screen for glucocorticoid receptor translocation was able to predict assay-specific biological activity in two ongoing drug discovery projects, leading to a tremendous 60-fold and 250-fold increase of hit rates.
For transcriptomic data, models are reported by Aliper et al. [14] where several hundred compounds selected from Broad LINCS database are linked to 12 therapeutic use categories in breast cancer (MCF7), prostate cancer (PC3), and lung cancer cells (A549).
The aim of the current study was to compare the performances of descriptors derived from gene expression and phenotypic profiling assays with the performance of chemical structure based descriptors for prediction of various drug mechanisms of action and target proteins. To this end, models for several hundred mechanism(s) of actions and/or protein target(s) (MoA/Ts) were created using data for 1484 compounds characterized in both gene expression and phenotypic profiling assays.
As L1000 gene expression profiles have been collected systematically in several cell lines, we also aimed to investigate cell-context specificity of transcriptomic data for predicting MoA/Ts.
In phenotyping profiling, each compound is typically tested in quadruplicates or octaplicates on different plates and thus four or eight profiles per compound are obtained. The overall profile thus depends on the way the data are aggregated. In this study we therefore also investigated effects of data pre-processing on the prediction accuracy. 
Annotation of compounds with protein targets and/or mechanism of action
We used Touchstone data base ( https://clue.io/touchstone ) [6] and Drug Repurposing Hub ( https://clue.io/repurposing ) [16] to associate compounds to their mechanism(s) of actions and/or protein target(s) (MoA/Ts). From annotations to individual targets, we also derived labels for protein kinase groups.
For Phenotypic profiling dataset, we obtained annotations for 1759 compounds, where 257 MoA/Ts were shared by at least five compounds. In CMap dataset, the three cell lines with the highest number of annotated compounds were MCF7 (breast cancer, 2801 annotated compounds, 444 MoA/Ts shared by at least five compounds), PC3 (prostate cancer, 2775 annotated compounds, 435 MoA/Ts), and A549 (lung cancer, 2319 annotated compounds, 380 MoA/Ts). The intersection of Phenotypic profiling dataset and the largest of CMap datasets (MCF7) contained 1484 compounds and 234 MoA/Ts.
Data pre-processing
In Phenotypic profiling dataset, most of the compounds have been applied to cells eight times on different plates, thus giving eight sets of morphological features for each compound. In data pre-processing, we first centered and (optionally) normalized the features on plate-to-plate basis, by subtracting the mean value and (optionally) dividing by standard deviation for the control samples on this plate. Thereafter we calculated the mean or the median values of each feature from the eight sets, and used them as descriptors for the compounds. Some of 1783 features were invariant in the present dataset, and were removed before the modelling.
Random Forest
Random Forest (RF) is a classifier that consists of multiple decision trees. A decision tree is made of nodes and branches. At each node the dataset is split based on the value of some attribute that is selected so that the instances of different classes are predominantly moved to different branches. Classification starts at the root node and is performed by passing the instances along the tree to leaf nodes. To introduce diversity between the trees of a random forest, a subset of all attributes is randomly selected to take decisions at each node of each tree. The class probability of an instance is estimated considering results of all trees. We here developed RF models with 500 trees using the randomForest package of R. Thus, for a test set instance the class probability was one of 500 numerical values in the range from 0 to 1.
Evaluation of modeling performance
For every MoA/T, 25 RF models were created, assigning 80% of compounds to the training set and 20% of compounds to the prediction set. The predictions from all models were aggregated to calculate Receiver Operating Characteristic (ROC) curve, which is plotted as the true positive rate versus the false positive rate at various discrimination threshold values. The area under the ROC curve (AUC) is a measure of the discriminatory power of a classifier, which is insensitive to class distributions and the costs of misclassifications; AUC = 1 indicates perfect classification, while AUC = 0.5 means that the classifier does not perform better than random guessing.
Results and Discussion
Models for CMap datasets in three cell lines
In CMap dataset, the three cell lines with the highest number of annotated compounds were MCF7 (breast cancer, 2801 annotated compounds, PC3 (prostate cancer, 2775 annotated compounds), andA549 (lung cancer, 2319 annotated compounds).
We created Random Forest models for mechanisms of action and targets (MoA/Ts) shared by at least five compounds, which gave 444, 435, and 380 models for MCF7, PC3, and A549, In the presentation of CMap dataset, the authors noted that only 15% of compounds produced highly similar transcriptional profiles across the entire panel of cell-lines suggesting that transcriptional response is cell dependent [7] . For instance, it was found that glucocorticoid receptor antagonists shared similar profiles only in cell lines where the glucocorticoid receptor NR3C1 was highly expressed (i.e. A549, but not PC3 and MCF7). Our results confirm this finding for glucocorticoid receptor agonists, where the models for A549 and PC3 cell lines show much better predictive performance than the model for MCF7. Similarly, for glycogen synthase kinase inhibitors good models are obtained in MCF7 and PC3, but not in A549 cell line, but for glutamate receptor modulators only in MCF7, and for estrogen receptor antagonists and agonists only in A549.
An overall comparisons of the models does not reveal, however, large differences between the cell lines, the average AUC for top-50 models in MCF7 being 0.85 and in the two other cell lines 0.82. An overview of results for the broadest drug classes indicates that gene expression data is not suited for modeling of GPCR-targeted drugs (such as agonists and antagonists of dopamine, histamine, serotonin, and acetylcholine receptors). For these mechanisms of action, the models show AUC around 0.50, i.e., they do not perform better than random guesses. In In the next step of the study we created models for a set of 1484 compounds that have been characterized in both gene expression and phenotypic profiling assays. For the sake of comparisons, we also created models using structural descriptors of molecules, calculated by Chemistry Development Kit package of R (rcdk). These descriptors include a variety of topological, geometrical, charge based and constitutional descriptors [17] .
The results for MoA/Ts where AUC for either gene expression or phenotypic profiling based model exceeded 0.70 are presented graphically in Figure 2 ; results for all 234 MoA/Ts are given in Supplementary Table 2 . In many cases, gene expression or phenotypic profiling models show comparable predictive performance. For some of the targets, however, only one of the two descriptions has produced a predictive model.
Similarly as with gene expression data, morphological profiling data has not given any predictive models for agonists/antagonists of most GPCR classes. This is in contrast to models for inhibitors of several protein kinases and protein kinase groups (such as non-receptor tyrosine kinases with AUC = 0.71) and for agonists/antagonists of nuclear receptors (e.g. estrogen and retinoid receptors with AUC > 0.75).
Our negative results for GPCRs are in agreement with findings of Rohban et. al. [17] who estimated similarities of morphological profiles of pairs of compounds sharing the same MoA. For GPCR agonists/antagonists it was found that a very low fraction of the top most-similar profiles were profiles of compounds with the same MoA. Thus, for the four largest groups of compounds in the dataset, agonists and antagonists of dopamine and serotonin receptor, only 0 -1% of top most-similar profiles belonged to another member of this group. (This can be compared to 5% for SRC inhibitors, where we got a predictive model with AUC = 0.78, 2% for tubulin EGFR inhibitor, where our model showed AUC = 0.80, and 96% for tubulin polymerization inhibitor, where our model showed AUC = 0.99).
In fact, for a multitude of MoA/Ts, the drug effect need not lead to profound morphological or transcriptional changes of cells. In profiling of 1600 known bioactive compounds by Cell Painting assay, Gustafsdottir et al. observed that only 13% of them could be deemed active, i.e. their profiles could be distinguished from the natural variation of profiles of untreated cells.
Another aspect that could be considered in phenotyping profiling is differences in pharmacokinetic/pharmacodynamic properties of chemical compounds. Because of these differences, imaging at one fixed data point may be suboptimal compared to temporal monitoring to observe maximum changes of cell morphology.
Models for Cell Painting dataset with different data pre-processing methods
We compared two pre-processing approaches: 1) centering of CellProfiler derived features on plate-to-plate basis by subtracting the mean value for the control samples on this plate and 2) centering and normalization by subtracting the mean and dividing by standard deviation for the control samples. In the latter case, use of some features was problematic because the values for control samples were invariant for part of the plates.
Thereafter we described the compounds by either the mean values or the median values from the eight feature sets (in the latter case, the three "weakest" and the three "strongest" changes in cell morphology are not considered).
Thus, four models were were created for each of 234 MoA/Ts. Overall, the results are very similar for most of MoA/Ts, the standard deviation calculated from the four AUC values being below 0.05, thus confirming reliability of the models. However, discrepancies can be observed for some MoA/Ts where the number of active compounds is low (see Supplementary Table 3) .
